Technical Analysis for MRUS - Merus N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.05% | |
| Outside Day | Range Expansion | 7.05% |
| Alert | Time |
|---|---|
| Up 2 ATRs | about 15 hours ago |
| Rose Above 50 DMA | about 16 hours ago |
| 50 DMA Resistance | about 16 hours ago |
| Up 5% | about 17 hours ago |
| Up 1 ATR | about 18 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 52.035 |
| 52 Week Low | 18.21 |
| Average Volume | 606,923 |
| 200-Day Moving Average | 30.62 |
| 50-Day Moving Average | 44.94 |
| 20-Day Moving Average | 42.69 |
| 10-Day Moving Average | 41.29 |
| Average True Range | 1.90 |
| RSI (14) | 58.85 |
| ADX | 19.13 |
| +DI | 26.34 |
| -DI | 13.68 |
| Chandelier Exit (Long, 3 ATRs) | 40.73 |
| Chandelier Exit (Short, 3 ATRs) | 44.96 |
| Upper Bollinger Bands | 46.42 |
| Lower Bollinger Band | 38.96 |
| Percent B (%b) | 0.8 |
| BandWidth | 17.47 |
| MACD Line | -0.71 |
| MACD Signal Line | -0.87 |
| MACD Histogram | 0.1639 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 51.76 | ||||
| Resistance 3 (R3) | 51.25 | 48.46 | 50.62 | ||
| Resistance 2 (R2) | 48.46 | 46.72 | 48.71 | 50.24 | |
| Resistance 1 (R1) | 46.69 | 45.64 | 47.58 | 47.21 | 49.86 |
| Pivot Point | 43.90 | 43.90 | 44.34 | 44.16 | 43.90 |
| Support 1 (S1) | 42.14 | 42.16 | 43.02 | 42.65 | 40.00 |
| Support 2 (S2) | 39.35 | 41.09 | 39.60 | 39.62 | |
| Support 3 (S3) | 37.58 | 39.35 | 39.24 | ||
| Support 4 (S4) | 38.10 |
